Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia

J Gastroenterol Hepatol. 2010 May:25 Suppl 1:S122-8. doi: 10.1111/j.1440-1746.2009.06218.x.

Abstract

Background and aims: It is still controversial which drugs, proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2RA), are more effective for dyspepsia in the Japanese population.

Methods: Patients with uninvestigated dyspepsia (n = 104; male/female 41/63) were treated with either rabeprazole 10 mg o.d. (n = 62) or lafutidine 10 mg b.i.d. (n = 42) for 4 weeks. Questionnaires (modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease [mFSSG] and quality of life [QOL], SF-8) were administered before and after therapy. The mFSSG was classified into a total score (Q-T), reflux score (Q-R), dyspepsia score (Q-D) and pain score (Q-P). The SF-8 had a physical component summary (PCS) and mental component summary (MCS). The predominant type of symptom was reflux (R-S), pain (P-S) or dysmotility (D-S).

Results: R-S was 19.2%, P-S 48.1%, D-S 24.0% and overlap 8.7%. In the R-S, Q-T and Q-R significantly improved with rabeprazole, but neither scale improved with lafutidine. MCS significantly improved with rabeprazole. In P-S, Q-T, Q-R, Q-D and Q-P significantly improved with both drugs. PCS significantly improved with both, whereas the MCS significant improved with rabeprazole. In D-S, Q-R and Q-D significant improved with rabeprazole, but neither improved with lafutidine. QOL did not improve with either. With overlap, neither scale nor the QOL reached a significant difference.

Conclusion: Both PPI and H2RA have a positive effect on P-S, but H(2)RA therapy is limited for R-S and D-S, whereas PPI therapy is generally effective. Therefore, careful prescription based on symptoms is important.

Publication types

  • Comparative Study

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
  • Acetamides / therapeutic use*
  • Adult
  • Dyspepsia / complications
  • Dyspepsia / drug therapy*
  • Esophageal Motility Disorders / drug therapy
  • Esophageal Motility Disorders / etiology
  • Female
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / etiology
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Pain / drug therapy
  • Pain / etiology
  • Pain Measurement
  • Piperidines / therapeutic use*
  • Proton Pump Inhibitors / therapeutic use*
  • Pyridines / therapeutic use*
  • Rabeprazole
  • Retrospective Studies
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Acetamides
  • Histamine H2 Antagonists
  • Piperidines
  • Proton Pump Inhibitors
  • Pyridines
  • Rabeprazole
  • lafutidine